Clinical characteristics of patients
| Characteristic . | All cohort (n = 359) . | aGVHD cohort (n = 263) . | cGVHD cohort (n = 207) . |
|---|---|---|---|
| Follow-up, mo | |||
| Median (range) | 32 (4-105) | 23 (1-104) | 33 (4-104) |
| Age, y | |||
| Median (range) | 45 (0-68) | 44 (0-68) | 42 (0-68) |
| Patient sex, n (%) | |||
| Male | 225 (63) | 166 (63) | 131 (63) |
| Female | 134 (37) | 97 (37) | 76 (37) |
| Donor sex, n (%) | |||
| Male | 201 (56) | 147 (56) | 115 (55) |
| Female | 158 (44) | 116 (44) | 92 (45) |
| Donor/recipient sex, n (%) | |||
| Female donor/male recipient | 91 (25) | 69 (26) | 53 (26) |
| Disease, n (%) | |||
| AML | 116 (32) | 73 (28) | 52 (25) |
| ALL | 49 (13.5) | 37 (14) | 30 (14.5) |
| NHL, HD | 54 (15) | 39 (15) | 29 (14) |
| Myelofibrosis, MDS | 34 (9.5) | 25 (9.5) | 19 (9) |
| MM | 33 (9) | 25 (9.5) | 18 (9) |
| Other (CML, AA, etc) | 73 (20) | 25 (9.5) | 59 (28.5) |
| Conditioning regimen, n (%) | |||
| Myeloablative | 253 (70) | 170 (65) | 144 (70) |
| Reduced intensity | 106 (30) | 93 (35) | 63 (30) |
| With TBI | 94 (26) | 71 (27) | 59 (28.5) |
| GVHD prophylaxis, n (%) | |||
| CsA + MTX | 290 (81) | 220 (83.5) | 165 (79.7) |
| CsA ± steroids | 8 (2) | 4 (1.5) | 3 (1.3) |
| Others | 61 (17) | 39 (15) | 39 (18) |
| Stem-cell source, n (%) | |||
| Peripheral blood | 250 (69.6) | 178 (68) | 133 (64) |
| Bone marrow | 109 (30.4) | 85 (32) | 74 (36) |
| aGVHD grade, n (%) | |||
| 2-4 | 115 (32) | 74 (28) | 48 (23) |
| 3-4 | 50 (14) | 29 (11) | 21 (10) |
| cGVHD, n (%) | |||
| Global | 161 (45) | 142 (54) | 109 (53) |
| Extensive | 100 (28) | 84 (32) | 63 (30) |
| Mortality, n (%) | |||
| Incidence | 86 (24) | 27 | 31 |
| Relapse, n (%) | |||
| Incidence | 105 (30) | 74 (28) | 53 (26) |
| Death, n (%) | |||
| Incidence | 154 (43) | 96 (37) | 54 (26) |
| Characteristic . | All cohort (n = 359) . | aGVHD cohort (n = 263) . | cGVHD cohort (n = 207) . |
|---|---|---|---|
| Follow-up, mo | |||
| Median (range) | 32 (4-105) | 23 (1-104) | 33 (4-104) |
| Age, y | |||
| Median (range) | 45 (0-68) | 44 (0-68) | 42 (0-68) |
| Patient sex, n (%) | |||
| Male | 225 (63) | 166 (63) | 131 (63) |
| Female | 134 (37) | 97 (37) | 76 (37) |
| Donor sex, n (%) | |||
| Male | 201 (56) | 147 (56) | 115 (55) |
| Female | 158 (44) | 116 (44) | 92 (45) |
| Donor/recipient sex, n (%) | |||
| Female donor/male recipient | 91 (25) | 69 (26) | 53 (26) |
| Disease, n (%) | |||
| AML | 116 (32) | 73 (28) | 52 (25) |
| ALL | 49 (13.5) | 37 (14) | 30 (14.5) |
| NHL, HD | 54 (15) | 39 (15) | 29 (14) |
| Myelofibrosis, MDS | 34 (9.5) | 25 (9.5) | 19 (9) |
| MM | 33 (9) | 25 (9.5) | 18 (9) |
| Other (CML, AA, etc) | 73 (20) | 25 (9.5) | 59 (28.5) |
| Conditioning regimen, n (%) | |||
| Myeloablative | 253 (70) | 170 (65) | 144 (70) |
| Reduced intensity | 106 (30) | 93 (35) | 63 (30) |
| With TBI | 94 (26) | 71 (27) | 59 (28.5) |
| GVHD prophylaxis, n (%) | |||
| CsA + MTX | 290 (81) | 220 (83.5) | 165 (79.7) |
| CsA ± steroids | 8 (2) | 4 (1.5) | 3 (1.3) |
| Others | 61 (17) | 39 (15) | 39 (18) |
| Stem-cell source, n (%) | |||
| Peripheral blood | 250 (69.6) | 178 (68) | 133 (64) |
| Bone marrow | 109 (30.4) | 85 (32) | 74 (36) |
| aGVHD grade, n (%) | |||
| 2-4 | 115 (32) | 74 (28) | 48 (23) |
| 3-4 | 50 (14) | 29 (11) | 21 (10) |
| cGVHD, n (%) | |||
| Global | 161 (45) | 142 (54) | 109 (53) |
| Extensive | 100 (28) | 84 (32) | 63 (30) |
| Mortality, n (%) | |||
| Incidence | 86 (24) | 27 | 31 |
| Relapse, n (%) | |||
| Incidence | 105 (30) | 74 (28) | 53 (26) |
| Death, n (%) | |||
| Incidence | 154 (43) | 96 (37) | 54 (26) |
Table lists characteristics used to build the predictive models with LASSO (aGVHD, n = 263; cGVHD, n = 207; NRM, n = 359).
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CsA, cyclosporin A; HD, Hodgkin disease; MDS, myelodysplastic syndrome; MM, multiple myeloma; MTX, methotrexate; NHL, non-Hodgkin lymphoma;